Last reviewed · How we verify
ICS/LABA medication
ICS/LABA combines an inhaled corticosteroid to reduce airway inflammation with a long-acting beta-2 agonist to relax airway smooth muscle and improve bronchodilation.
ICS/LABA combines an inhaled corticosteroid to reduce airway inflammation with a long-acting beta-2 agonist to relax airway smooth muscle and improve bronchodilation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | ICS/LABA medication |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | ICS/LABA combination |
| Target | Beta-2 adrenergic receptor (LABA component); glucocorticoid receptor (ICS component) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The inhaled corticosteroid (ICS) component suppresses inflammatory pathways in the airways, reducing mucus production and airway edema. The long-acting beta-2 agonist (LABA) binds to beta-2 adrenergic receptors on airway smooth muscle, causing sustained bronchodilation over 12-24 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for improved airflow and symptom control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Nervousness/anxiety
Key clinical trials
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
- Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Eosinophil-guided Reduction of Inhaled Corticosteroids (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICS/LABA medication CI brief — competitive landscape report
- ICS/LABA medication updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI